When Amgen won FDA approvals to make a biosimilar drug that mimicked Humira, Abbvie’s blockbuster drug for treating rheumatoid arthritis, Crohns and ulcerative colitis, Abbvie sued, claiming Amgen was violating its patent protections. But instead of a battle of the Titans, the two drug giants quickly reached an agreement: in which Amgen got the greenlight to sell its biosimilar in Europe and agreed not to make its biosimilar available in the U.S. until 2023 – bad news for U.S. consumers. If “Amgen were able to enter the [U.S.] market before 2023 it would have offered consumers competition and lower prices,” said Michael Carrier, a Rutgers University law professor. “Now as a result of this settlement, prices [for Humira in the U.S.] will stay at the monopoly level for the next five years.”


Sources: Chicago Tribune.

Share This